| Not Yet Recruiting | This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autol NCT07412405 | GUSTAVO SALGUERO | N/A |
| Not Yet Recruiting | variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway NCT07463976 | The Royal Wolverhampton Hospitals NHS Trust | — |
| Not Yet Recruiting | Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL NCT07516093 | Nurix Therapeutics, Inc. | Phase 3 |
| Recruiting | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Vir NCT07020533 | City of Hope Medical Center | Phase 1 |
| Not Yet Recruiting | Evaluation of Skin Tests in Biotherapy Allergies NCT06971848 | University Hospital, Angers | N/A |
| Not Yet Recruiting | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NCT07520006 | Nurix Therapeutics, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors NCT07526597 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Recruiting | Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Sub NCT06863402 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymph NCT07218341 | Eli Lilly and Company | Phase 4 |
| Recruiting | A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymp NCT07271667 | Curis, Inc. | Phase 2 |
| Enrolling By Invitation | Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials NCT07474051 | AvenCell Therapeutics, Inc. | — |
| Recruiting | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acal NCT07277231 | BeOne Medicines | Phase 3 |
| Not Yet Recruiting | Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously U NCT07321652 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Recruiting | Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemi NCT07218510 | City of Hope Medical Center | Phase 2 |
| Not Yet Recruiting | A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in P NCT06792994 | German CLL Study Group | — |
| Recruiting | Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus NCT07288515 | AstraZeneca | — |
| Recruiting | Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL NCT07014917 | Zulfa Omer | Phase 2 |
| Not Yet Recruiting | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/ NCT07225439 | Paolo Caimi, MD | Phase 1 |
| Recruiting | Mosunetuzumab for CLL MRD Clearance NCT07052695 | Inhye Ahn | Phase 1 / Phase 2 |
| Recruiting | Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia NCT07099443 | Nantes University Hospital | N/A |
| Recruiting | A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Ch NCT06520098 | VA Office of Research and Development | Phase 2 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Ref NCT06973187 | BeOne Medicines | Phase 3 |
| Recruiting | Study of Epcoritamab as a Consolidation Therapy in CLL/SLL NCT07108998 | Zulfa Omer | Phase 2 |
| Recruiting | Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patient NCT06967610 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalab NCT06839872 | AstraZeneca | Phase 2 |
| Not Yet Recruiting | Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic NCT07003464 | The First Hospital of Jilin University | Phase 2 |
| Recruiting | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituxi NCT06943872 | BeOne Medicines | Phase 3 |
| Recruiting | Combating Cancer-Related Fatigue: A Personalized Supportive Care Program NCT06860880 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lym NCT06839053 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of NCT06978088 | Zulfa Omer | Phase 2 |
| Not Yet Recruiting | Time Restricted Eating in Haematological Malignancies NCT06862323 | British Columbia Cancer Agency | Phase 2 |
| Recruiting | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579 | Vironexis Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lympho NCT06970743 | BeOne Medicines | Phase 3 |
| Recruiting | A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib NCT06876649 | Eli Lilly and Company | Phase 4 |
| Recruiting | A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Smal NCT06876662 | Eli Lilly and Company | Phase 4 |
| Recruiting | Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL NCT06849713 | Massachusetts General Hospital | Phase 2 |
| Recruiting | Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanu NCT06812715 | Peter MacCallum Cancer Centre, Australia | Phase 2 |
| Recruiting | AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATO NCT06548152 | AstraZeneca | — |
| Recruiting | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Sm NCT06846671 | BeOne Medicines | Phase 3 |
| Recruiting | Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) NCT06644183 | Jennifer R. Brown, MD, PhD | Phase 1 / Phase 2 |
| Not Yet Recruiting | Effects of a Strength Physical Exercise Program in Chronic Lymphocytic Leukemia Patients NCT06654206 | University of Salamanca | EARLY_Phase 1 |
| Recruiting | Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment NCT06784167 | OHSU Knight Cancer Institute | — |
| Recruiting | 64Cu-LLP2A for Imaging Hematologic Malignancies NCT06636175 | Washington University School of Medicine | EARLY_Phase 1 |
| Active Not Recruiting | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relaps NCT06291220 | AbbVie | Phase 1 |
| Active Not Recruiting | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participant NCT06697184 | BeiGene | Phase 1 / Phase 2 |
| Recruiting | A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chroni NCT06588478 | Loxo Oncology, Inc. | Phase 2 |
| Active Not Recruiting | A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With P NCT06637501 | BeOne Medicines | Phase 2 |
| Recruiting | Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BT NCT06466122 | Kerry Rogers | Phase 2 |
| Enrolling By Invitation | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas NCT07168486 | University of Maryland, Baltimore | Phase 1 |
| Recruiting | Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Ly NCT06544785 | PETHEMA Foundation | Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inh NCT06524375 | Genentech, Inc. | Phase 2 |
| Recruiting | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in NCT06428019 | AbbVie | Phase 3 |
| Not Yet Recruiting | Biological and Clinical Efficacy of Shingrix in Patients With CLL NCT06364033 | Gruppo Italiano Malattie EMatologiche dell'Adulto | N/A |
| Not Yet Recruiting | Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL) NCT06416267 | University of Haifa | — |
| Recruiting | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Pat NCT06059391 | City of Hope Medical Center | Phase 2 |
| Not Yet Recruiting | Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia Patients NCT05899543 | Power Life Sciences Inc. | — |
| Not Yet Recruiting | Polymorphism of ITGA4 Gene in Chronic Lymphocytic Leukemia NCT05371392 | Sohag University | — |
| Not Yet Recruiting | Familial B-cell Lymphoproliferative Disorders NCT05718986 | University of Haifa | — |
| Not Yet Recruiting | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL NCT06367374 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Withdrawn | Cardiotoxicities in Patients Receiving BTKi NCT05521178 | Dana-Farber Cancer Institute | — |
| Unknown | Preliminary Assessment of [18F]BL40 in PET/CT Scans NCT06224309 | British Columbia Cancer Agency | — |
| Not Yet Recruiting | Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Rea NCT06084923 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia NCT06333262 | Inhye Ahn | Phase 2 |
| Recruiting | A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated C NCT05950997 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Enrolling By Invitation | Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors NCT06211413 | Abramson Cancer Center at Penn Medicine | — |
| Recruiting | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter' NCT06043674 | Christine Ryan | Phase 2 |
| Recruiting | Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Mali NCT06151730 | Mayo Clinic | — |
| Active Not Recruiting | Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic NCT06547944 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Active Not Recruiting | Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia NCT05971251 | University of Alabama at Birmingham | Phase 1 |
| Recruiting | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in NCT06136559 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania NCT06170671 | AstraZeneca | — |
| Active Not Recruiting | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantati NCT06001385 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Recruiting | Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL NCT05694312 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Recruiting | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, NCT05702853 | Medical University of South Carolina | Phase 1 / Phase 2 |
| Recruiting | A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic NCT06125795 | AbbVie | — |
| Not Yet Recruiting | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens NCT04790045 | Paolo Ghia | Phase 4 |
| Recruiting | A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chroni NCT05959694 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leu NCT05943496 | OHSU Knight Cancer Institute | Phase 1 |
| Withdrawn | Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL NCT05465876 | Sunnybrook Health Sciences Centre | Phase 2 |
| Active Not Recruiting | Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant NCT04167683 | Rigshospitalet, Denmark | — |
| Recruiting | Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia NCT05417165 | Seema Bhat | Phase 2 |
| Unknown | Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis Wit NCT05803395 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Active Not Recruiting | Exercise As Intervention in Chronic Lymphocytic Leukemia NCT06396611 | Universidade do Porto | N/A |
| Active Not Recruiting | Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancie NCT05797233 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Acalabrutinib Real World Italian obSErvational Study -ARISE NCT06205498 | AstraZeneca | — |
| Recruiting | Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies NCT06037018 | CytoCares Inc | Phase 1 |
| Recruiting | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma NCT05602363 | Carna Biosciences, Inc. | Phase 1 |
| Active Not Recruiting | Biomarker for Infection Risk in CLL and MM NCT05844033 | Massachusetts General Hospital | — |
| Recruiting | A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia NCT05672355 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD T NCT05478512 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Active Not Recruiting | PICAROS - Acalabrutinib RWE on 1L CLL in Spain NCT05999877 | AstraZeneca | — |
| Completed | A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic NCT06362044 | AbbVie | — |
| Unknown | Ibrutinib Adapted to Response in Patients With CLL NCT05360758 | Grupo Argentino de Tratamiento de la Leucemia Aguda | — |
| Active Not Recruiting | Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia o NCT05718869 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocy NCT05879133 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) NCT05878184 | Sana Biotechnology | Phase 1 |
| Recruiting | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves NCT05512390 | AbbVie | Phase 1 |
| Recruiting | Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019 | Schrödinger, Inc. | Phase 1 |
| Recruiting | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies NCT05618028 | AbbVie | Phase 1 |
| Active Not Recruiting | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic NCT05624554 | Merck Sharp & Dohme LLC | Phase 3 |
| Unknown | Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies NCT05739227 | Xuzhou Medical University | EARLY_Phase 1 |
| Active Not Recruiting | Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia NCT05677919 | Mayo Clinic | Phase 2 |
| Recruiting | Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic NCT05371808 | Canadian Cancer Trials Group | — |
| Completed | Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and S NCT05694364 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic NCT05388006 | Mayo Clinic | Phase 2 |
| Recruiting | Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors NCT05643235 | Northwell Health | N/A |
| Recruiting | Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation NCT04935684 | University Hospital, Clermont-Ferrand | Phase 2 |
| Completed | A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) R NCT05555979 | AbbVie | — |
| Active Not Recruiting | Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomi NCT05556720 | Monash University | Phase 3 |
| Terminated | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small NCT05317936 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia NCT06379282 | University of Surrey | N/A |
| Terminated | RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia NCT05405309 | University of Utah | Phase 1 / Phase 2 |
| Recruiting | Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymp NCT05336812 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | National Acalabrutinib Observational Study NCT05437250 | AstraZeneca | — |
| Suspended | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbet NCT05400122 | David Wald | Phase 1 |
| Withdrawn | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies NCT04282174 | Baptist Health South Florida | Phase 2 |
| Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection NCT05334069 | Alliance for Clinical Trials in Oncology | — |
| Recruiting | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/S NCT05254743 | Loxo Oncology, Inc. | Phase 3 |
| Active Not Recruiting | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive an NCT05458297 | Merck Sharp & Dohme LLC | Phase 2 |
| Withdrawn | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CA NCT05037669 | University of Pennsylvania | Phase 1 |
| Recruiting | In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia) NCT04785989 | University of Wisconsin, Madison | — |
| Completed | MargheRITA (Remote Intelligence for Therapeutic Adherence) NCT05260203 | Advice Pharma Group srl | N/A |
| Unknown | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies NCT05410041 | Beijing Boren Hospital | Phase 1 |
| Recruiting | Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Pr NCT06475469 | CHU de Reims | N/A |
| Withdrawn | Early Intervention With Acalabrutinib in Patients With High Risk CLL NCT04660045 | Weill Medical College of Cornell University | Phase 2 |
| Recruiting | Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lym NCT05326308 | iOMEDICO AG | — |
| Recruiting | A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previou NCT05197192 | German CLL Study Group | Phase 3 |
| Recruiting | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukem NCT05281809 | John Lister | Phase 2 |
| Recruiting | AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry NCT06250465 | Arbeitsgemeinschaft medikamentoese Tumortherapie | — |
| Terminated | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies NCT05107856 | Prelude Therapeutics | Phase 1 |
| Unknown | Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL NCT05287984 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia NCT05246345 | University Hospital, Clermont-Ferrand | — |
| Recruiting | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosun NCT05091424 | Hoffmann-La Roche | Phase 1 |
| Recruiting | Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancer NCT04844528 | University of Utah | Phase 2 |
| Completed | Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Of NCT06782854 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associa NCT05183854 | University of Utah | Phase 2 |
| Completed | Financial Difficulty in Patients With Blood Cancer NCT05212233 | UNC Lineberger Comprehensive Cancer Center | — |
| Terminated | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutatio NCT05153330 | Biomea Fusion Inc. | Phase 1 |
| Recruiting | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL NCT05147467 | Ascentage Pharma Group Inc. | Phase 2 |
| Terminated | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndro NCT04978779 | Vincerx Pharma, Inc. | Phase 1 |
| Recruiting | Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL NCT04908228 | Paolo Ghia | Phase 2 |
| Completed | Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia NCT04964908 | AstraZeneca | — |
| Active Not Recruiting | CLL Therapy Approaches in Russia NCT05140369 | AstraZeneca | — |
| Recruiting | Two Step Haplo With Radiation Conditioning NCT05031897 | Thomas Jefferson University | Phase 2 |
| Recruiting | Study on the Diagnosis and Management of CLL in Italy by GIMEMA NCT04867915 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | MEOI and HRQoL in CLL Patients Treated With BTKis NCT04938141 | AstraZeneca | — |
| Completed | Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia NCT05093192 | University of Bath | N/A |
| Unknown | Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients NCT04640909 | Gruppo Italiano Malattie EMatologiche dell'Adulto | N/A |
| Active Not Recruiting | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide NCT04904588 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Recruiting | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation NCT04679012 | Weill Medical College of Cornell University | Phase 2 |
| Active Not Recruiting | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic NCT05023980 | Loxo Oncology, Inc. | Phase 3 |
| Active Not Recruiting | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) i NCT04965493 | Loxo Oncology, Inc. | Phase 3 |
| Terminated | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refra NCT04809467 | Incyte Corporation | Phase 1 / Phase 2 |
| Unknown | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma NCT05020392 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 3 |
| Recruiting | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies NCT05006716 | BeOne Medicines | Phase 1 / Phase 2 |
| Unknown | Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutati NCT04980859 | Nanfang Hospital, Southern Medical University | Phase 3 |
| Recruiting | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CM NCT04771572 | Newave Pharmaceutical Inc | Phase 1 |
| Active Not Recruiting | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell NCT05020678 | Nkarta, Inc. | Phase 1 |
| Completed | COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies NCT05028374 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Active Not Recruiting | FT819 in Subjects With B-cell Malignancies NCT04629729 | Fate Therapeutics | Phase 1 |
| Terminated | Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML NCT04887259 | Lava Therapeutics | Phase 1 |
| Unknown | B-cell Chronic Lymphoid Malignancies Markers NCT04952974 | University Hospital, Strasbourg, France | — |
| Completed | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candid NCT05972577 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL NCT04722172 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | A Study of FCN-338 in Patients With Chronic CLL/SLL NCT04682808 | Fochon Pharmaceuticals, Ltd. | Phase 1 |
| Active Not Recruiting | huCART19-IL18 in CD19+ Cancers NCT04684563 | University of Pennsylvania | Phase 1 |
| Unknown | Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients NCT04691765 | Dr. David Spaner | Phase 1 |
| Active Not Recruiting | Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies NCT04732845 | Benjamin Tomlinson | Phase 1 |
| Active Not Recruiting | Safe Accelerated Venetoclax Escalation in CLL NCT04843904 | Dana-Farber Cancer Institute | Phase 1 |
| Unknown | Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies NCT04796675 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Terminated | Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications NCT04595851 | University of Michigan Rogel Cancer Center | N/A |
| Unknown | Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors NCT04814004 | Kai Lin Xu; Jun Nian Zheng | Phase 1 |
| Terminated | Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymph NCT04852822 | University of Washington | — |
| Active Not Recruiting | Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic NCT04657094 | City of Hope Medical Center | Phase 2 |
| Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients NCT04858568 | University Hospital Southampton NHS Foundation Trust | — |
| Active Not Recruiting | Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus NCT04666038 | Loxo Oncology, Inc. | Phase 3 |
| Recruiting | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Le NCT04269902 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphom NCT04419389 | Aprea Therapeutics | Phase 1 / Phase 2 |
| Completed | A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leu NCT04657224 | Janssen Research & Development, LLC | Phase 1 |
| Unknown | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL NCT04502394 | Kartos Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced NCT04504708 | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy NCT04149821 | Weill Medical College of Cornell University | Phase 2 |
| Unknown | Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence NCT04663100 | University of Tennessee | N/A |
| Active Not Recruiting | ALICIA (Acalabrutinib in CLL Therapy) NCT04746950 | AstraZeneca | — |
| Unknown | Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL NCT04862806 | Bnai Zion Medical Center | N/A |
| Unknown | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL NCT04578613 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 |
| Unknown | MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies NCT04370457 | Centre for Research and Technology Hellas | N/A |
| Completed | Personalized Multi-peptide Vaccination in CLL Patients NCT04688385 | University Hospital Tuebingen | Phase 1 |
| Withdrawn | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lym NCT04694560 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCT NCT05928156 | Duke University | N/A |
| Active Not Recruiting | Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL NCT04624633 | Jennifer R. Brown, MD, PhD | Phase 2 |
| Completed | Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia NCT04512105 | University of California, Irvine | Phase 1 |
| Withdrawn | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 201 NCT04665115 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL NCT04560322 | Massachusetts General Hospital | Phase 2 |
| Terminated | The clonoSEQ® Watch Registry NCT04545333 | Adaptive Biotechnologies | — |
| Completed | Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Pa NCT04502030 | Octapharma | Phase 3 |
| Withdrawn | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL NCT03639324 | Virginia Commonwealth University | Phase 1 |
| Completed | SARS-CoV-2 Donor-Recipient Immunity Transfer NCT04666025 | City of Hope Medical Center | — |
| Terminated | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, NCT04553692 | IGM Biosciences, Inc. | Phase 1 |
| Terminated | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma NCT04189952 | University of Miami | Phase 2 |
| Completed | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Trea NCT04312841 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Terminated | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL NCT04240704 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL NCT04494503 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Recruiting | Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia NCT04505254 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax NCT04501939 | University of California, San Diego | Phase 2 |
| Recruiting | Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clin NCT04282811 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Active Not Recruiting | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers NCT04464200 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia NCT04616274 | National Taiwan University Hospital | — |
| Unknown | Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia NCT05145101 | Hannah Garcia Garrido | — |
| Unknown | A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma NCT04356846 | The First Affiliated Hospital with Nanjing Medical University | Phase 1 |
| Completed | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab NCT04282018 | BeiGene | Phase 1 / Phase 2 |
| Terminated | Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL NCT04342117 | SecuraBio | — |
| Completed | BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) NCT04018248 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL NCT04030195 | Precision BioSciences, Inc. | Phase 1 / Phase 2 |
| Terminated | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies NCT04245722 | Fate Therapeutics | Phase 1 |
| Completed | Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newl NCT04774744 | M.D. Anderson Cancer Center | N/A |
| Terminated | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas NCT04358458 | Genmab | Phase 1 / Phase 2 |
| Withdrawn | Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance NCT03943342 | Kerry Rogers | Phase 2 |
| Completed | DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer NCT04282343 | Barbara Ann Karmanos Cancer Institute | N/A |
| Completed | Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL NCT04155710 | Iovance Biotherapeutics, Inc. | Phase 1 |
| Withdrawn | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies NCT04043845 | Dana-Farber Cancer Institute | Phase 1 |
| Terminated | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or NCT04155840 | University of Washington | Phase 2 |
| Active Not Recruiting | A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece NCT04159779 | AbbVie | — |
| Terminated | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignan NCT04160195 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation NCT04060277 | City of Hope Medical Center | Phase 2 |
| Terminated | TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) NCT04163718 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma NCT03892044 | David Bond, MD | Phase 1 |
| Recruiting | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies NCT03765177 | Ottawa Hospital Research Institute | Phase 1 / Phase 2 |
| Unknown | Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice NCT04094051 | The First Affiliated Hospital with Nanjing Medical University | — |
| Completed | Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients NCT04008706 | AstraZeneca | Phase 3 |
| Active Not Recruiting | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial NCT03844048 | AbbVie | Phase 3 |
| Completed | Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT NCT04716075 | Polish Lymphoma Research Group | Phase 2 |
| Active Not Recruiting | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant NCT03622788 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic NCT04016805 | TG Therapeutics, Inc. | Phase 2 |
| Unknown | A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients NCT04059081 | Deok-Hwan Yang | Phase 2 |
| Active Not Recruiting | Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL NCT03960840 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL NCT03986034 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Terminated | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL NCT03572634 | Sumitomo Pharma America, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies NCT03913949 | Ascentage Pharma Group Inc. | Phase 1 |
| Terminated | Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia NCT03514017 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Terminated | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared NCT03801525 | TG Therapeutics, Inc. | Phase 2 / Phase 3 |
| Terminated | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders NCT03601819 | University of Michigan Rogel Cancer Center | Phase 1 |
| Recruiting | A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With NCT03980002 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Completed | Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma NCT03870633 | Alliance for Clinical Trials in Oncology | — |
| Terminated | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas NCT03893682 | Aptose Biosciences Inc. | Phase 1 |
| Completed | Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia. NCT03939234 | Lars Møller Pedersen | Phase 2 |
| Active Not Recruiting | Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistanc NCT03513562 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Unknown | Evaluation of the Redox Profiles of Healthy and Pathological B Cells in Patients With Chronic Lymphocytic Leuk NCT03971565 | Assistance Publique Hopitaux De Marseille | — |
| Completed | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL NCT03740529 | Loxo Oncology, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001 NCT03833180 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Terminated | Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL NCT03708003 | Swiss Cancer Institute | Phase 2 |
| Recruiting | Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refra NCT03666000 | Imugene Limited | Phase 1 |
| Active Not Recruiting | Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgki NCT03884998 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA10 NCT03836261 | Acerta Pharma BV | Phase 3 |
| Active Not Recruiting | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymph NCT03701282 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab NCT03545035 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Active Not Recruiting | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab NCT03737981 | National Cancer Institute (NCI) | Phase 3 |
| Withdrawn | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Bloo NCT03438344 | City of Hope Medical Center | Phase 2 |
| Unknown | Chronic Lymphocytic Leukemia Responds to Dermal Chelation NCT03495492 | Optimum Health, Natural Healthcare Center | N/A |
| Completed | The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib NCT03528941 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia NCT03609593 | Nicole Lamanna | Phase 2 |
| Completed | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoi NCT03734601 | Stanford University | Phase 2 |
| Completed | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocyt NCT03734016 | BeiGene | Phase 3 |
| Unknown | Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their Effect NCT03881592 | Brno University Hospital | — |
| Terminated | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies NCT03671590 | TG Therapeutics, Inc. | Phase 1 |
| Recruiting | Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia NCT03516617 | Mayo Clinic | Phase 2 |
| Recruiting | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-gener NCT03676504 | University Hospital Heidelberg | Phase 1 / Phase 2 |
| Unknown | Observational Study of Ibrutinib Use in CLL NCT03633045 | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health | — |
| Completed | Exercise Training to Promote Resilience to Chronic Lymphocytic Leukemia NCT04950452 | Duke University | N/A |
| Active Not Recruiting | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Tran NCT03560752 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia NCT03447808 | Jennifer Woyach | Phase 1 |
| Terminated | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors NCT03615105 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and C NCT03524235 | Noah Merin | Phase 1 |
| Active Not Recruiting | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS NCT03534323 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Terminated | A Study Of The Selective PKC-β Inhibitor MS- 553 NCT03492125 | MingSight Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Completed | Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) NCT03207555 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 NCT02890758 | Brenda Cooper, MD | Phase 1 |
| Active Not Recruiting | Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib NCT03422393 | Michael Choi | Phase 1 |
| Active Not Recruiting | A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL NCT03467867 | Georgetown University | Phase 2 |
| Recruiting | Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma NCT03501576 | Emory University | — |
| Unknown | Gazyva Infusion Reaction Investigation NCT03529227 | Healthy Future | — |
| Recruiting | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Active Not Recruiting | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression NCT03480360 | Dartmouth-Hitchcock Medical Center | Phase 3 |
| Terminated | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With NCT03379051 | TG Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously U NCT03374137 | Hoffmann-La Roche | — |
| Completed | A Study of BNC105P Combined With Ibrutinib NCT03454165 | Dartmouth-Hitchcock Medical Center | Phase 1 |
| Completed | A Prognostic Tool for Early Stage CLL NCT03436524 | Oncology Institute of Southern Switzerland | — |
| Recruiting | A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) NCT04771507 | Jeanette Lundin | Phase 1 / Phase 2 |
| Terminated | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product NCT03436771 | Juno Therapeutics, a Subsidiary of Celgene | — |
| Withdrawn | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic NCT03370185 | SecuraBio | Phase 2 |
| Withdrawn | Lenalidomide and Obinutuzumab for Previously Untreated CLL NCT02371590 | University of California, San Diego | Phase 2 |
| Active Not Recruiting | A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL NCT03328273 | Acerta Pharma BV | Phase 1 |
| Completed | Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leuk NCT03310190 | AbbVie | — |
| Terminated | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Long-term Follow-up Study of Patients Receiving CAR-T Cells NCT03375619 | Medical College of Wisconsin | — |
| Terminated | Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requi NCT03153514 | German CLL Study Group | Phase 2 |
| Unknown | Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemi NCT04754035 | Paolo Ghia | Phase 2 |
| Active Not Recruiting | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL NCT03336333 | BeiGene | Phase 3 |
| Completed | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractor NCT03263637 | AstraZeneca | Phase 1 |
| Completed | Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell NCT03019055 | Medical College of Wisconsin | Phase 1 |